Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $105.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price hoisted by Oppenheimer from $95.00 to $105.00 in a research note issued to investors on Wednesday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Several other research firms have also issued reports on TARS. Guggenheim increased their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Barclays started coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Mizuho began coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.00.

Tarsus Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ:TARS opened at $75.52 on Wednesday. The company has a current ratio of 3.85, a quick ratio of 4.25 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25. The business has a 50 day moving average of $72.00 and a two-hundred day moving average of $68.61. The company has a market capitalization of $3.21 billion, a PE ratio of -46.62 and a beta of 0.57.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. As a group, analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider owned 38,958 shares in the company, valued at $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after purchasing an additional 1,217 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Tarsus Pharmaceuticals by 2.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after buying an additional 1,394 shares in the last quarter. Jane Street Group LLC grew its holdings in Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after buying an additional 190,000 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $227,000. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 15.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock worth $420,000 after acquiring an additional 1,418 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.